Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ChemoCentryx, Inc. (NASDAQ: CCXI).

Full DD Report for CCXI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CCXI)

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
Reader Inquiry: Is InflaRx A Buy On The Dip?
Shares of InflaRx N.V. ( IFRX ) have risen by over 60% year to date and at one point almost tripled from their IPO price point (from last November). After their IPO the stock popped back on my radar after it appeared in a recent edition of my Institutional Top Ideas series as one of the to...
Source: SeekingAlpha
Date: May, 13 2018 02:13
ChemoCentryx's (CCXI) CEO Dr. Thomas Schall on Q1 2018 Results - Earnings Call Transcript
ChemoCentryx, Inc. (CCXI) Q1 2018 Results Earnings Conference Call May 09, 2018 05:00 PM ET Executives Steve Klass - VP, Burns McClellan Dr. Thomas Schall - President and CEO Susan Kanaya - EVP, Chief Financial and Administrative Officer Analysts Tessa Romero - JP Morgan ...
Source: SeekingAlpha
Date: May, 09 2018 20:53
ChemoCentryx beats by $0.04, beats on revenue
ChemoCentryx (NASDAQ: CCXI ): Q1 EPS of -$0.19 beats by $0.04 . More news on: ChemoCentryx, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:11
ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights
-- Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) -- -- Ongoing clinical trials with avacopan in C3 Glo...
Source: GlobeNewswire
Date: May, 09 2018 16:05
ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech
Image from Company's Website After getting my toes wet in the renal-disease space with my previous overview article , I came across two companies I really like: Achillion ( ACHN ) and ChemoCentryx ( CCXI ). Ra Pharmaceuticals ( RARX ) and Omeros ( OMER ) are both contenders with potential...
Source: SeekingAlpha
Date: May, 07 2018 11:18
ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018
MOUNTAIN VIEW, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018. ChemoCentryx executive management will host a conference call and...
Source: GlobeNewswire
Date: May, 02 2018 08:30
Premarket analyst action - healthcare
ChemoCentryx (NASDAQ: CCXI ) initiated with Buy rating and $20 (82% upside) price target at H.C.Wainwright. More news on: ChemoCentryx, Mallinckrodt PLC, Ironwood Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 02 2018 08:18
Free Research Report as ChemoCentryx's Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
Stock Monitor: Altimmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on ChemoCentryx, Inc. (NASDAQ: CCXI ). If you want access to this report all you need to do is sign up now by clicking the follow...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:40
ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
MOUNTAIN VIEW, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of avacopan in t...
Source: GlobeNewswire
Date: April, 11 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1712.5012.4712.9011.8751463,017
2017-02-027.347.167.347.1082,211
2017-02-017.337.327.427.2776,922
2017-01-317.137.277.307.03147,187
2017-01-307.267.167.286.95103,078

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2017,60734,20351.4779Short
2018-08-176,66027,50324.2155Cover
2018-08-164,37024,13718.1050Cover
2018-08-1520,40465,73131.0417Cover
2018-08-1464,354160,05640.2072Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CCXI.


About ChemoCentryx, Inc. (NASDAQ: CCXI)

Logo for ChemoCentryx, Inc. (NASDAQ: CCXI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CCXI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 06 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: CCXI)

      Daily Technical Chart for (NASDAQ: CCXI)


      Stay tuned for daily updates and more on (NASDAQ: CCXI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CCXI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CCXI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CCXI and does not buy, sell, or trade any shares of CCXI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/